Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Abselion logo — Precision Made Practical

Abselion

Precision Made Practical

Founded 2017 United Kingdom Cambridge, United Kingdom 29 employees Seed Total: $1.90M Biotechnology

General Information

Company Name Abselion
Founded Year 2017
Location United Kingdom Cambridge, United Kingdom
Employees 29
Industries Biotechnology
Funding Stage Seed
Business Model B2B, Platform
Revenue Model Product Sales, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with Abselion. To contact Abselion, visit abselion.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Abselion compare?

A PDF of Abselion and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Abselion soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Abselion

Abselion, founded in 2017 and headquartered in the United Kingdom, is at the forefront of simplifying protein research. Their mission is encapsulated in their slogan: "Protein research made simple." The company operates within the Biotechnology industry, focusing on providing tools to accelerate biotherapeutics development. Through their proprietary Redox Electrochemical Detection (RED) technology, the award-winning Amperia system offers a novel approach to biologics and viral-vector quantification, allowing for automated, cost-effective titre measurement.

Abselion's technology emphasizes high automation and minimal hands-on time, empowering scientists to focus on innovative bioprocess optimization. Their dynamic team, blending biology, nanotechnology, and data science, thrives in a flat hierarchy fostering idea-sharing and passion. As of their last investment on 20 April 2021, Abselion secured a £1.90M Seed Round backed by investors like Parkwalk Advisors, New Ground Ventures, University of Cambridge Enterprise, Swiss Health Angels, and R42 Group.

Business keywords: protein research, biomolecules, data science, nanotechnology, medicine development, molecular interactions, biological analysis, automation tools, interdisciplinary team, dynamic work environment

Services & Products

Biologic quantification tools
Amperia™ platform for measurement
Protein and viral vector analysis
Assay kits and reagents
Validated sensors for lab use

Target Customers

Research laboratories Bioprocessing researchers Biotechnologies companies Life sciences institutions Pharmaceutical R&D departments

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round £1.90M 5
Parkwalk Advisors New Ground Ventures
Parkwalk Advisors, New Ground Ventures +3
20 Apr 2021

Abselion Alternatives & Competitors

View All Alternatives
Abselion vs
NanoTemper Technologies
NanoTemper Technologies Germany

Tools made for drug discovery. Built for momentum.

186 employees
Biotechnology
Abselion vs
Protein Lounge
Protein Lounge United States

Protein Lounge is a biological Animation, Pathway, and Graphics provider for the biotech and pharmac...

Seed
22 employees
Biotechnology, Data Analytics
Abselion vs
Adaptyv
Adaptyv Switzerland

The cloud lab for protein designers

Series A
40 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Abselion

Precision Made Practical
Abselion was founded in 2017.
Abselion is headquartered in Cambridge, United Kingdom.
Abselion operates in Biotechnology. Its work centres on protein research, biomolecules, data science and nanotechnology. Its customers include Research laboratories, Bioprocessing researchers and Biotechnologies companies.
Abselion has a B2B and Platform business model. Its revenue comes from Product Sales and Usage Based.
Abselion has approximately 29 employees.
Abselion has completed 1 funding round, raising a total of $1.90M. The latest funding stage is Seed.
Abselion offers: Biologic quantification tools, Amperia™ platform for measurement, Protein and viral vector analysis, Assay kits and reagents, Validated sensors for lab use.
Top alternatives and competitors to Abselion include NanoTemper Technologies, Protein Lounge, Adaptyv, Magnet Biomedicine, Fluidic Analytics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Abselion and NanoTemper Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Abselion, https://bouncewatch.com/company/abselion, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout